- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03284814
Bioavailability Study of CoQ10 Formulations in Healthy Elderly Adults (CoQ10-01)
March 18, 2019 updated by: Snežana Kocijančič, Nutrition Institute, Slovenia
Single-dose and Multiple-dose Comparative Bioavailability Study of Three CoQ10 Formulations in Healthy Elderly Adults
The single-center, randomized, open-label, three-period crossover bioavailability study will include 21 subjects who will test three CoQ10 formulations.
Subjects will test 3 formulations of single dose CoQ10 within first 3 weeks to assess bioavailability, which will be followed with 2 weeks of continuous administration of one of study formulations to demonstrate and assesse multiple-dose profile of CoQ10.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
- Dietary supplement: Single dose intervention with Standard product (SP)
- Dietary supplement: Single dose intervention with Comparative product (CP)
- Dietary supplement: Single dose intervention with Investigational product (IP)
- Dietary supplement: Multiple dose intervention with Standard product (SP)
- Dietary supplement: Multiple dose intervention with Comparative product (CP)
- Dietary supplement: Multiple dose intervention with Investigational product (IP)
Study Type
Interventional
Enrollment (Actual)
21
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ljubljana, Slovenia, 1000
- Nutrition Institute, Ljubljana
-
Ljubljana, Slovenia, 1000
- MEDEDUS, Ljubljana, Slovenia
-
Ljubljana, Slovenia, 1000
- Vizera d.o.o., Ljubljana, Slovenia
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
63 years to 72 years (Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject Informed consent form (ICF) is singed
- Aged between 65 and 74 years at the time of the signature of ICF
- A body mass index between 20 and 29 kg/m2
- Healthy, meaning absence of any prescribed medication for a month prior to the inclusion to the study and during the study
- Willing to avoid a consumption of any food supplements except vitamin D and calcium at least 2 weeks before and during the study
- Consumption of dairy and cereal products (standardised breakfast will include low lactose dairy and bread)
- Willing to follow all study procedures, including attending all site visits (including sessions during which a venous line will be inserted for blood sampling), and keeping a diary for the time of multiple-dose study (to follow their compliance and palatability)
Exclusion Criteria:
- Intake of any prescribed medication within 2 weeks of the beginning of the study
- Intake of any food supplements within 2 weeks of the beginning of the study, except vitamin D and calcium
- Hypotension
- Any clinically significant history of serious digestive tract, liver, kidney, cardiovascular or hematological disease, diabetes
- Gastrointestinal disorders or other serious acute or chronic diseases
- Known lactose/gluten intolerances/ food allergies (limitation for standardisation of meals)
- Inadequate veins (in the opinion of the investigator) or known contraindication to placement of a dedicated peripheral line for venous blood withdrawal
- Known drug and/or alcohol abuse
- Using any form of nicotine or tobacco
- Mental incapacity that precludes adequate understanding or cooperation
- Participation in another investigational study or blood donation within 3 months prior to or during this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Standard product group
This group will be included in a single dose cross over study, and in multiple dose study with standard product (SP: CoQ10 hard capsules; 100 mg)
|
hard capsules, 100 mg
soft-gel capsules, 100 mg
syrup, 100 mg
hard capsules, 100 mg - 14 days
|
Active Comparator: Comparative product group
This group will be included in a single dose cross over study, and in multiple dose study with comparative product (CP: CoQ10 soft-gel capsules; 100 mg)
|
hard capsules, 100 mg
soft-gel capsules, 100 mg
syrup, 100 mg
soft-gel capsules, 100 mg - 14 days
|
Experimental: Investigational product group
This group will be included in a single dose cross over study, and in multiple dose study with investigational product (IP: CoQ10 syrup; 100 mg)
|
hard capsules, 100 mg
soft-gel capsules, 100 mg
syrup, 100 mg - 14 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
improved single dose bioavailability of IP (in comparison to SP)
Time Frame: 48 hours
|
Relative bioavailability between the investigational and standard product expressed as ratio of AUC0-48h (area under the plasma concentration curve from the administration time to the last observation point, i.e. 48h) of total CoQ10 plasma concentrations above the baseline value.
|
48 hours
|
improved plasma CoQ10 level after multiple dose study for IP (in comparison to SP)
Time Frame: 14 days
|
Ratio between total CoQ10 trough plasma concentrations after multiple-dose application on day 14 (CMIN,day14) between the investigational and standard product.
|
14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
comparable single dose bioavailability of IP (in comparison to CP)
Time Frame: 48 hours
|
Relative bioavailability between the investigational product and comparator expressed as ratio of AUC0-48h of total CoQ10 plasma concentrations above the baseline value.
|
48 hours
|
comparable plasma CoQ10 level after multiple dose study for IP (in comparison to CP)
Time Frame: 14 days
|
Ratio between total CoQ10 trough plasma concentrations after multiple-dose application on day 14 (CMIN,day14) between the investigational product and comparator.
|
14 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Igor Pravst, Nutrition Institute, Ljubljana
- Principal Investigator: Snežana Kocijančič, MEDEDUS, Ljubljana, Slovenia
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 29, 2017
Primary Completion (Actual)
October 20, 2017
Study Completion (Actual)
October 20, 2017
Study Registration Dates
First Submitted
September 13, 2017
First Submitted That Met QC Criteria
September 13, 2017
First Posted (Actual)
September 15, 2017
Study Record Updates
Last Update Posted (Actual)
March 20, 2019
Last Update Submitted That Met QC Criteria
March 18, 2019
Last Verified
March 1, 2019
More Information
Terms related to this study
Other Study ID Numbers
- KME 89/07/17
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bioavailability of Coenzyme Q10
-
Nutrition Institute, SloveniaVizera d.o.o.; ADM, Ambulanta družinske medicine, Ljubljana, Slovenia; Adrialab... and other collaboratorsCompletedBioavailability of Coenzyme Q10Slovenia
-
Factors Group of Nutritional Companies Inc.IsuraCompleted
-
Centre d'Alt RendimentUniversity of Barcelona; Indena S.p.A; Hospital Sant Joan de DeuCompletedBioavailability and Impact of Coenzyme Q10 in Stressing Exercise in Senescence Athletes (CoQ10Sport)Aging | Oxidative Stress | Coenzyme Q10Spain
-
Karachi Medical and Dental CollegeCompleted
-
Maimónides Biomedical Research Institute of CórdobaUnknownCoenzyme Q10 on Athero-thrombosis in APS PatientsSpain
-
VA Office of Research and DevelopmentCompletedGulf War Illness | Chronic Fatigue | Coenzyme Q10 | UbiquinolUnited States
-
Edda Sciutto CondeCompletedBioavailability of Methylprednisolone Intranasally | Bioavailability of Methylprednisolone Intravenously | Comparison Intranasally vs IntravenouslyMexico
-
USDA, Western Human Nutrition Research CenterCompletedBioavailability of CarotenoidsUnited States
-
The University of Texas Health Science Center at...CompletedBioavailability of PhytonutrientsUnited States
-
AronPharma Sp. z o. o.CompletedBioavailability of Vitamin DPoland
Clinical Trials on Single dose intervention with Standard product (SP)
-
Nutrition Institute, SloveniaVizera d.o.o.; ADM, Ambulanta družinske medicine, Ljubljana, Slovenia; Adrialab... and other collaboratorsCompletedBioavailability of Coenzyme Q10Slovenia
-
Masaryk Memorial Cancer InstituteRecruiting
-
Knopp BiosciencesBiogenCompleted
-
GlaxoSmithKlineCompleted
-
The Hospital for Sick ChildrenCanadian Institutes of Health Research (CIHR)Completed
-
Kyoung Ho Lee, MDSeoul National University Bundang Hospital; Ministry of Health & Welfare, Korea and other collaboratorsCompleted
-
University Hospital, GhentCompleted
-
Hospital of South West JutlandKolding SygehusActive, not recruitingEnd-stage Renal Disease (ESRD)Denmark
-
GlaxoSmithKlineCompletedInfection, Human Immunodeficiency Virus
-
Fluart Innovative Vaccine Ltd, HungaryCompleted